Salesforce
CRM
Adobe
ADBE
NVIDIA
NVDA
Oracle
ORCL
Amazon
AMZN
US Stock MarketDetailed Quotes
RNAZ Transcode Therapeutics
- 9.520
- +0.488+5.40%
Trading Dec 4 15:52 ET
4.98MMarket Cap-333P/E (TTM)
9.890High8.150Low107.66KVolume8.850Open9.032Pre Close952.34KTurnover20.59%Turnover RatioLossP/E (Static)523.20KShares288.02452wk High3.01P/B4.98MFloat Cap7.12852wk Low--Dividend TTM523.02KShs Float184800.000Historical High--Div YieldTTM19.26%Amplitude7.128Historical Low8.845Avg Price1Lot Size
About Transcode Therapeutics Company
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
Company Profile
SymbolRNAZ
Company NameTranscode Therapeutics
Listing DateJul 9, 2021
Issue Price4.00
Founded2016
CEOMr. Thomas A. Fitzgerald, M.B.A.
MarketNASDAQ
Employees10
Fiscal Year Ends12-31
Address73b Chapel Street
CityNewton
ProvinceMassachusetts
CountryUnited States of America
Zip Code02458
Phone1-857-837-3099
Company Executives
- Name
- Position
- Salary
- Thomas A. Fitzgerald, M.B.A.
- Interim President, Chief Executive Officer, Director, Vice President, Chief Financial Officer and Principal Accounting Officer
- 426.86K
- Dr. Zdravka Medarova
- Chief Scientific Officer
- --
- Dr. Philippe P. Calais, PhD
- Executive Chairman of the Board
- 112.61K
- Dr. Erik Manting, PhD
- Independent Director
- 73.11K
- Dr. Magda Marquet, PhD
- Independent Director
- 75.11K
- Dr. Anna Moore, PhD
- Scientific Advisor
- --